Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 09, 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Jun 08, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 18, 2020
Akcea Announces Appointment of New Chief Financial Officer
May 14, 2020
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 07, 2020
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 05, 2020
Akcea Reports Financial Results and Highlights for First Quarter 2020
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
May 01, 2019
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Aug 02, 2018
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
Mar 26, 2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
Mar 15, 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Sep 05, 2017
Innovative Medicines Canada welcomes Akcea Therapeutics Canada and Ipsen Biopharmaceuticals Canada as its newest members
Jul 27, 2017
Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
Jun 20, 2017
Akcea Therapeutics Launches Proposed Initial Public Offering